Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXI NASDAQ:IOBT NASDAQ:PPBT NASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.24-13.3%$0.39$0.15▼$0.97$915K-0.096,905 shs3,235 shsIOBTIO Biotech$0.05$0.08$0.03▼$2.79$3.45M0.887.09 million shsN/APPBTPurple Biotech$2.88+6.7%$4.05$2.52▼$29.00$3.47M0.68328,705 shs47,537 shsSXTP60 Degrees Pharmaceuticals$1.48-0.7%$1.74$1.29▼$14.68$3.96M2.6951,406 shs49,619 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics-13.25%-19.70%-53.67%+60.60%+9.45%IOBTIO Biotech0.00%0.00%0.00%-85.88%-95.68%PPBTPurple Biotech+6.67%-26.90%-41.82%-41.83%-87.85%SXTP60 Degrees Pharmaceuticals-0.67%+6.47%-17.78%-51.63%-84.26%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXIAvenue Therapeutics$0.24-13.3%$0.39$0.15▼$0.97$915K-0.096,905 shs3,235 shsIOBTIO Biotech$0.05$0.08$0.03▼$2.79$3.45M0.887.09 million shsN/APPBTPurple Biotech$2.88+6.7%$4.05$2.52▼$29.00$3.47M0.68328,705 shs47,537 shsSXTP60 Degrees Pharmaceuticals$1.48-0.7%$1.74$1.29▼$14.68$3.96M2.6951,406 shs49,619 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXIAvenue Therapeutics-13.25%-19.70%-53.67%+60.60%+9.45%IOBTIO Biotech0.00%0.00%0.00%-85.88%-95.68%PPBTPurple Biotech+6.67%-26.90%-41.82%-41.83%-87.85%SXTP60 Degrees Pharmaceuticals-0.67%+6.47%-17.78%-51.63%-84.26%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXIAvenue Therapeutics 0.00N/AN/AN/AIOBTIO Biotech 1.60Reduce$3.507,191.67% UpsidePPBTPurple Biotech 2.00Hold$30.00941.67% UpsideSXTP60 Degrees Pharmaceuticals 2.00Hold$13.85835.81% UpsideCurrent Analyst Ratings BreakdownLatest ATXI, SXTP, PPBT, and IOBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026SXTP60 Degrees Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.20 ➝ $3.705/20/2026SXTP60 Degrees Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/4/2026PPBTPurple Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/13/2026PPBTPurple Biotech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/9/2026SXTP60 Degrees Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.20 ➝ $4.203/27/2026IOBTIO Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026SXTP60 Degrees Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/13/2026PPBTPurple Biotech Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/13/2026PPBTPurple Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$34.00 ➝ $30.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/AIOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/APPBTPurple BiotechN/AN/AN/AN/A$7.52 per shareN/ASXTP60 Degrees Pharmaceuticals$1.41M2.79N/AN/A($1.81) per share-0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXIAvenue Therapeutics-$10.38M-$0.530.01N/AN/AN/A-471.57%-296.50%8/10/2026 (Estimated)IOBTIO Biotech-$95.49M-$1.35N/AN/AN/AN/A-517.22%-200.69%N/APPBTPurple Biotech-$26.39M-$18.84N/AN/AN/AN/A-123.63%-98.72%8/5/2026 (Estimated)SXTP60 Degrees Pharmaceuticals-$7.36M-$8.92N/AN/AN/A-574.91%N/A-131.48%N/ALatest ATXI, SXTP, PPBT, and IOBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2026Q1 2026PPBTPurple Biotech-$0.38-$0.09+$0.29$0.09N/AN/A5/15/2026Q1 2026SXTP60 Degrees Pharmaceuticals-$0.76-$1.28-$0.52-$1.28$0.44 million$0.16 million3/13/2026Q4 2025PPBTPurple Biotech-$3.40-$19.85-$16.45$200.00N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATXIAvenue TherapeuticsN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXIAvenue TherapeuticsN/A2.702.70IOBTIO Biotech18.292.012.01PPBTPurple BiotechN/A1.481.27SXTP60 Degrees PharmaceuticalsN/A3.342.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXIAvenue Therapeutics17.34%IOBTIO Biotech54.76%PPBTPurple Biotech9.64%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipATXIAvenue Therapeutics8.60%IOBTIO Biotech2.30%PPBTPurple Biotech2.98%SXTP60 Degrees Pharmaceuticals1.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXIAvenue Therapeutics43.30 million2.02 millionNot OptionableIOBTIO Biotech3071.95 million68.50 millionNot OptionablePPBTPurple Biotech201.28 million1.25 millionOptionableSXTP60 Degrees Pharmaceuticals32.66 million2.61 millionNot OptionableATXI, SXTP, PPBT, and IOBT HeadlinesRecent News About These Companies60 Degrees Pharmaceuticals (NASDAQ:SXTP) Price Target Cut to $3.70 by Analysts at Ascendiant Capital MarketsMay 23 at 4:05 AM | americanbankingnews.comHC Wainwright & Co. downgrades 60 Degrees Pharmaceuticals (SXTP)May 21 at 1:27 AM | msn.com60 Degrees Pharmaceuticals Announces First Quarter 2026 ResultsMay 15, 2026 | globenewswire.com60 Degrees Pharmaceuticals (SXTP) Projected to Post Quarterly Earnings on ThursdayMay 14, 2026 | americanbankingnews.com60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38April 30, 2026 | msn.com60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel WebsiteApril 15, 2026 | markets.businessinsider.com60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should KnowApril 3, 2026 | zacks.comInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comFInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comF60 Degrees Pharmaceuticals Announces 2025 Annual ResultsMarch 31, 2026 | globenewswire.com60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut ExtractMarch 18, 2026 | globenewswire.com60 Degrees Pharmaceuticals Updates Opinion for ATM ProgramMarch 14, 2026 | theglobeandmail.comWhat's going on with 60 Degrees Pharmaceuticals on Friday?March 13, 2026 | msn.com60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical TrialMarch 11, 2026 | globenewswire.com60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODAFebruary 24, 2026 | insidermonkey.com60 Degrees Pharmaceuticals (SXTP) price target increased by 300.00% to 17.95February 4, 2026 | msn.com60 Degrees Pharmaceuticals shares slide after unveiling GoodRx collaborationFebruary 2, 2026 | msn.com60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx PartnershipFebruary 2, 2026 | globenewswire.com60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx UseJanuary 29, 2026 | finance.yahoo.com60 Degrees Pharmaceuticals shares slide after Nasdaq flags delisting riskJanuary 26, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATXI, SXTP, PPBT, and IOBT Company DescriptionsAvenue Therapeutics NASDAQ:ATXI$0.24 -0.04 (-13.25%) As of 05/22/2026 03:20 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.IO Biotech NASDAQ:IOBT$0.05 0.00 (0.00%) As of 04/7/2026IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Purple Biotech NASDAQ:PPBT$2.88 +0.18 (+6.67%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.70 -0.18 (-6.25%) As of 05/22/2026 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.60 Degrees Pharmaceuticals NASDAQ:SXTP$1.48 -0.01 (-0.67%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.50 +0.02 (+1.01%) As of 05/22/2026 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
